New indication granted for Repatha for wider group of patients: Adults with CVD
from Pharmacy Practice News
The FDA granted a new indication for evolocumab (Repatha, Amgen) as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease (CVD).
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063